DR Congo Tries Experimental mAb114 To Treat Ebola
Democratic Republic of Congo has begun using the experimental mAb114 Ebola treatment on patients in the east of the country, the health ministry disclosed today.
It is the first time it has been deployed against an active outbreak.
In a statement, the ministry also said the outbreak in eastern Congo’s North Kivu province has now spread to neighbouring Ituri province, where a person who was a confirmed case died after returning home from the flare-up’s epicentre in the North Kivu town of Mangina.
Five new cases have been confirmed, the ministry said, bringing the total number of cases to 57.
The ministry said that 41 people are believed to have died in all from the haemorrhagic fever.
The mAb114 treatment was developed in the US by the National Institutes of Health using the antibodies of the survivor of an Ebola outbreak in the western Congolese city of Kikwit in 1995.
It was 100 per cent effective when tested on monkeys.
The ministry said that several other experimental treatments have arrived in the regional hub of Beni and are awaiting approval from an ethics committee, including Remdesivir, Favipiravir and REGN3450, REGN3471 and REGN3479.